E. Zhu
Impact in
- Oncology top 10%
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- COVID-19 and healthcare impacts
-
- Prostate Cancer Treatment and Research
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
Papers in
-
- Lymphoma Diagnosis and Treatment 3
- Genetic factors in colorectal cancer 1
-
- Ovarian cancer diagnosis and treatment 2
- Co-authors
- K.N. Chi (1 shared paper)Primo N. Lara (1 shared paper)Shinta Cheng (1 shared paper)John M. Freedman (1 shared paper)Jason M. Summa (1 shared paper)Matthew Raymond Smith (1 shared paper)William Kevin Kelly (1 shared paper)Shahneen Kaur Sandhu (1 shared paper)
- Partner nations
- AustraliaFranceUnited States
In The Last Decade
E. Zhu
4 papers receiving 1.1k citations
E. Zhu's Hit Papers
Peers
Comparison fields: 5 of 113
- Oncology 465
- Pulmonary and Respiratory Medicine 339
- Cancer Research 131
- Hepatology 57
- Pathology and Forensic Medicine 85
Countries citing papers authored by E. Zhu
This map shows the geographic impact of E. Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Zhu more than expected).
Fields of papers citing papers by E. Zhu
This network shows the impact of papers produced by E. Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Zhu. The network helps show where E. Zhu may publish in the future.
Co-authors
The 25 scholars most cited alongside E. Zhu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial. Hit paper breakdown → | 2011 | 1133 |
| 2 | 2019 | 82 | |
| 3 | Efficacy and safety of bortezomib-rituximab (VCR) vs rituximab® in patients (PTS) with relapsed, R-naive/-sensitive follicular lymphoma (FL): outcome according to prior therapy | 2011 | 2 |
| 4 | FCGR3A polymorphism does not significantly affect response and outcome of follicular lymphoma patients treated in the PRIMA study with rituximab and chemotherapy followed by rituximab maintenance or observation | 2011 | 1 |
About E. Zhu
E. Zhu is a scholar working on Pathology and Forensic Medicine, Reproductive Medicine, Dermatology, Neurology and Oncology, having authored 4 papers that have together received 1.2k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (3 papers), Ovarian cancer diagnosis and treatment (2 papers), Prostate Cancer Treatment and Research (1 paper), PARP inhibition in cancer therapy (1 paper), Integrated Circuits and Semiconductor Failure Analysis (1 paper), Genetic factors in colorectal cancer (1 paper), CNS Lymphoma Diagnosis and Treatment (1 paper) and Cutaneous lymphoproliferative disorders research (1 paper). The work is most often cited by research in Oncology (465 citations), Pulmonary and Respiratory Medicine (339 citations), Cancer Research (131 citations), Hepatology (57 citations) and Pathology and Forensic Medicine (85 citations). E. Zhu has collaborated with scholars based in Australia, France and United States. Frequent co-authors include K.N. Chi, Primo N. Lara, Shinta Cheng, John M. Freedman, Jason M. Summa, Matthew Raymond Smith, William Kevin Kelly, Shahneen Kaur Sandhu, Fred Saad and Karim S. Fizazi. Their work appears in journals such as Annals of Oncology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.